Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Berney DM (2022)

Publication Type: Journal article

Publication year: 2022

Journal

DOI: 10.1016/j.eururo.2022.09.015

Authors with CRIS profile

Involved external institutions

University of Alabama at Birmingham (UAB) United States (USA) (US) The University of Tennessee Health Science Center United States (USA) (US) Medizinische Universität Wien Austria (AT) University of Sydney (USYD) Australia (AU) Universitätsspital Zürich (USZ) Switzerland (CH) Homi Bhabha National Institute (HBNI) India (IN) Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi Italy (IT) Universität Bern Switzerland (CH) University of Toronto Canada (CA) Singapore General Hospital Singapore (SG) Memorial Sloan Kettering Cancer Center United States (USA) (US) Aichi Medical University Hospital / 愛知医科大学病院 Japan (JP) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) International Agency for Research on Cancer (IARC) France (FR) Queen Mary, University of London United Kingdom (GB)

How to cite

APA:

Netto, G.J., Amin, M.B., Compérat, E.M., Gill, A.J., Hartmann, A., Moch, H.,... Berney, D.M. (2022). Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. European Urology. https://dx.doi.org/10.1016/j.eururo.2022.09.015

MLA:

Netto, George J., et al. "Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification." European Urology (2022).

BibTeX: Download